RYTM

RHYTHM PHARMACEUTICALS INC

Data as of 2026 Q2 (06-30) · 13F snapshot

Summary

RHYTHM PHARMACEUTICALS INC (RYTM) is held as common stock by 8 tracked hedge-fund managers, with a combined reported value of ~$876.07M; the largest are Baker Bros. Advisors, Ken Griffin, Steven Cohen. 1 tracked manager also disclosed PUT or CALL positions, reported separately below. This quarter: 1 new, 1 added, 5 trimmed. 1 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.

Attention · HighThis quarter · Cooling

Common-stock holders81 also report options

Congress trades1

Price$95.71vs quarter-end-13.80%

Sectors0

This quarter's moves

New1

Added1

Trimmed / sold5

Top holderBaker Bros. Advisors

Common-stock positions

PUT and CALL disclosures are excluded from these holder counts and values.

Baker Bros. AdvisorsHold

Value $622.27M3.1% of portfolio5,604,4832026 Q2

Stanley DruckenmillerNew

Value $22.61M0.5% of portfolio203,6182026 Q2

Investor	Period	Value	Shares	% of portfolio	Action
Baker Bros. Advisors	2026 Q2	$622.27M	5,604,483	3.1%	Hold
Stanley Druckenmiller	2026 Q2	$22.61M	203,618	0.5%	New

PUT / CALL disclosures

Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.

Ken GriffinCALL—

Value $3.11M— of portfolio28,0002026 Q2

Ken GriffinPUT—

Value $1.94M— of portfolio17,5002026 Q2

Investor	Period	Value	Shares	% of portfolio	Action
Ken GriffinCALL	2026 Q2	$3.11M	28,000	—	—
Ken GriffinPUT	2026 Q2	$1.94M	17,500	—	—

Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.